Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
252.9 USD | +0.13% | -0.66% | +9.30% |
Mar. 28 | Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands | MT |
Mar. 15 | Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time | RE |
Financials (USD)
Sales 2024 * | 15.54B | Sales 2025 * | 16.67B | Capitalization | 46.03B |
---|---|---|---|---|---|
Net income 2024 * | 1.33B | Net income 2025 * | 1.58B | EV / Sales 2024 * | 3.74 x |
Net Debt 2024 * | 12.07B | Net Debt 2025 * | 11.65B | EV / Sales 2025 * | 3.46 x |
P/E ratio 2024 * |
34.6
x | P/E ratio 2025 * |
29
x | Employees | 87,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.76% |
Latest transcript on Iqvia Holdings Inc.
1 day | +0.13% | ||
1 week | -0.66% | ||
Current month | +2.32% | ||
1 month | +1.03% | ||
3 months | +8.66% | ||
6 months | +27.92% | ||
Current year | +9.30% |
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 62 | 16-10-02 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 20-07-31 |
James Berkshire
COO | Chief Operating Officer | 51 | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 16-10-02 |
Colleen Goggins
BRD | Director/Board Member | 68 | 17-07-26 |
Ari Bousbib
CEO | Chief Executive Officer | 62 | 16-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.67% | 0 M€ | 0.00% | - | |
3.45% | 0 M€ | 0.00% | - | |
2.92% | 1 M€ | -.--% | - | |
2.68% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 252.9 | +0.13% | 771,448 |
24-03-27 | 252.6 | +1.95% | 747,004 |
24-03-26 | 247.7 | -0.46% | 880,372 |
24-03-25 | 248.9 | -1.40% | 688,367 |
24-03-22 | 252.4 | -0.84% | 646,270 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B | |
-8.77% | 11.06B |